Acadia Pharmaceuticals (ACAD) Secures Patent And Phase 2 Progress, Is It 38% Below Fair Value?

Acadia Pharmaceuticals (ACAD) just stacked two key clinical milestones: a fresh USPTO Notice of Allowance extending potential ...

Acadia, Zydus patent litigation case looks resolved, says RBC

Investment firm RBC said the patent litigation between Acadia Pharmaceuticals (ACAD) and generic drugmaker Zydus over Nuplazid appears to have been resolved. Shares of Acadia Pharmaceuticals turned ...

Is Acadia Healthcare (ACHC) Outperforming Other Medical Stocks This Year?

Here is how Acadia Healthcare (ACHC) and Brookdale Senior Living (BKD) have performed compared to their sector so far this ...
StockStory.org on MSN

Acadia Healthcare (ACHC): Buy, sell, or hold post Q2 earnings?

Acadia Healthcare trades at $28.83 and has moved in lockstep with the market. Its shares have returned 13.5% over the last ...

Acadia Pharmaceuticals drops 7%, continuing fall after drug trial results

Acadia Pharmaceuticals ( ACAD) sank almost 7% on Friday, closing at $20.68 after a drop of $1.50. This came after a 13% drop ...
Fierce Biotech

Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuing

Acadia Pharmaceuticals’ phase 2 Alzheimer’s disease trial has missed its primary endpoint, but the company and analysts alike ...
Business Wire

Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE ™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older

-- First and only approved therapy for Rett syndrome, a rare, neurodevelopmental disorder, which affects 6,000 to 9,000 patients in the U.S. 1 SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc.
Forbes

2024 GMC Acadia Goes Big Again

Back in 2006, large 3-row crossover utility vehicles based on unibody, car-derived platforms rather than body-on-frame SUVs weren’t particularly common yet. The Honda Pilot and Toyota Highlander were ...